Table 3 Summary of findings table. Study characteristics for which data was extracted for each study are presented in this table. These include number of participants, length of follow-up, outcomes, relative risk and the GRADE assessment for quality of evidence and bias risk
RSV prophylaxis for prevention of recurrent childhood wheezing | ||||||||
|---|---|---|---|---|---|---|---|---|
Population: Pre-term and term infants Intervention: RSV prophylaxis (palivizumab/motavizumab) Comparison: No RSV prophylaxis | ||||||||
Study | No. of participants | Follow-up period | Outcomes | Intervention | Control | Relative risk (95% CI) | Quality of evidence GRADE | Comments |
Simoes EAF [32] | 421 | 2 Years | Wheeze | 25/191 | 59/230 | 0.51 (CI = 0.33 to 0.78) | LOW ++ | Observational cohort study |
No wheeze | 166/191 | 171/230 | ||||||
O’Brien KL [33] | 1919 | 3 Years | Wheeze | 35/1278 | 16/641 | 1.10 (CI = 0.61 to 1.97) | HIGH ++++ | Randomised control trial |
No wheeze | 1243/1278 | 625/641 | ||||||
Mochizuki H [34] | 440 | 6 Years | Wheeze | 44/345 | 68/95 | 0.18 (CI = 0.13 to 0.24) | LOW ++ | Case control |
No wheeze | 301/345 | 27/95 | ||||||
Carroll KN [35] | 6566 | 6 Years | Wheeze | 1056/4222 | 441/2344 | 1.33 (CI = 1.20 to 1.47) | VERY LOW + | Cohort study • Confounding by indication |
No wheeze | 2966/4222 | 1902/2344 | ||||||
Scheltema NM [36] | 395 | 6 Years | Wheeze | 28/199 | 47/196 | 0.59 (CI = 0.38 to 0.90) | HIGH ++++ | Randomised control trial |
No wheeze | 171/199 | 149/196 | ||||||
Igde M [37] | 339 | 3 years | Wheeze | 2/113 | 26/226 | 0.15 (CI = 0.038 to 0.63) | LOW ++ | Observational study |
No wheeze | 111/113 | 200/226 | ||||||
Simoes MC [38] | 445 | 3 Years (average) | Wheeze | 70/194 | 52/251 | 1.74 (CI = 1.28 to 2.37) | VERY LOW | Observational cross-sectional study • Confounding by indication |
No wheeze | 124/194 | 199/251 | ||||||
Moreno-Galdo A [39] | 670 | 3 Years | Wheeze | 7/108 | 82/562 | 0.44 (CI = 0.21 to 0.90) | LOW | Observational study |
No wheeze | 101/108 | 480/5562 | ||||||